This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
IGF1R alpha Monoclonal Antibody (24-31), Biotin
catalog :
MA5-13799
quantity :
500 µL
price :
US 496
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
24-31
reactivity :
human
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, chromatin immunoprecipitation, immunohistochemistry - paraffin section
citations: 22
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
| |
| Fidler M, Basu S, Buckingham L, Walters K, McCormack S, Batus M, et al. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012;32:1705-10 pubmed
|
| |
| |
| Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009;20:842-9 pubmed publisher
|
| |
| |
| |
| Hudelist G, Wagner T, Rosner M, Fink Retter A, Gschwantler Kaulich D, Czerwenka K, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer. 2007;14:1053-62 pubmed
|
| Harris L, You F, Schnitt S, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13:1198-207 pubmed
|
| Lopez Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amorós A, Tardon A, et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res. 2006;12:6029-36 pubmed
|
| Motoi N, Kishi K, Fujii T, Tsuboi E, Ohashi K, Yoshimura K. Multiple bronchioloalveolar carcinomas in acromegaly: a potential role of insulin-like growth factor I in carcinogenesis. Lung Cancer. 2006;54:247-53 pubmed
|
| Stefano J, Correa Giannella M, Ribeiro C, Alves V, Massarollo P, Machado M, et al. Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol. 2006;12:3821-8 pubmed
|
| Henriksen K, Rasmussen B, Lykkesfeldt A, Møller S, Ejlertsen B, Mouridsen H. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397-404 pubmed
|
| Kostler W, Hudelist G, Rabitsch W, Czerwenka K, Muller R, Singer C, et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol. 2006;132:9-18 pubmed
|
| Langner C, Ratschek M, Rehak P, Tsybrovskyy O, Zigeuner R. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?. BJU Int. 2005;95:310-4 pubmed
|
| Budde A, Schneiderhan Marra N, Petersen G, Brüne B. Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1). Oncogene. 2005;24:1802-8 pubmed
|
Singer C, Hudelist G, Lamm W, Mueller R, Czerwenka K, Kubista E. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer. 2004;11:861-9 pubmed
| |
Schips L, Zigeuner R, Ratschek M, Rehak P, Ruschoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol. 2004;122:931-7 pubmed
| |
Zhang P, Furth E, Cai X, Goldblum J, Pasha T, Min K. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol. 2004;35:670-4 pubmed
|
product information
Product Type :
Antibody
Product Name :
IGF1R alpha Monoclonal Antibody (24-31), Biotin
Catalog # :
MA5-13799
Quantity :
500 µL
Price :
US 496
Clonality :
Monoclonal
Purity :
Protein G
Host :
Mouse
Reactivity :
Human
Applications :
ELISA: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): Assay-dependent, Immunoprecipitation: 2 µg/mL
Species :
Human
Clone :
24-31
Isotype :
IgG1
Storage :
4° C
Description :
IGF1R (Insulin-like Growth Factor1 Receptor) is a receptor tyrosine kinase that mediates actions of insulin-like growth factor 1 (IFG1). It binds IGF1 with high affinity and IGF2/insulin with lower affinity. Activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survial of malignant cells. Ligand binding activates the receptor kinase and leads to receptor autophosphorylation and tyrosines phosphorylation of multiple substrates that function as signaling adapter proteins.
Immunogen :
IGF-1R/3T3 mouse fibroblasts transfected with human type I IGF-receptor cDNA
Format :
Liquid
Applications w/Dilutions :
ELISA: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): Assay-dependent, Immunoprecipitation: 2 µg/mL
Aliases :
A330103N21Rik; CD221; D930020L01; hyft; IGF-1 receptor; Igf1r; IGF-1R; IGF-I receptor; IGFIR; IGFIRC; IGFR; Igfr1; insulin like growth factor 1 receptor; insulin-like growth factor 1 receptor; Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain; insulin-like growth factor 1 receptor beta subunit; insulin-like growth factor I receptor; insulin-like growth factor receptor 1; insulin-like growth factor-I receptor; insulin-like growth factor-I receptor precursor; JTK13; line 186; soluble IGF1R variant 1; soluble IGF1R variant 2
company information

Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments